.Pharmacolibrary.Drugs.ATC.L.L01EB04

Information

Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M mutation-positive NSCLC. It is currently approved and widely used for this purpose.

Pharmacokinetics

Pharmacokinetic parameters of osimertinib in adult patients with advanced EGFR T790M mutation-positive NSCLC after oral administration.

References

1. Tsutani, Y, et al., & He, J (2023). Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical lung cancer 24(4) 376–380. DOI:10.1016/j.cllc.2023.02.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36872181

2. Johnson, M, et al., & Vishwanathan, K (2025). Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer. Pharmacology research & perspectives 13(3) e70098–None. DOI:10.1002/prp2.70098 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40289712

3. Ballard, P, et al., & Cross, D (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical cancer research : an official journal of the American Association for Cancer Research 22(20) 5130–5140. DOI:10.1158/1078-0432.CCR-16-0399 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27435396

Revisions

• 06/2025 initial generated model